Liontrust Investment Partners LLP Decreases Stake in Edwards Lifesciences Corporation $EW

Liontrust Investment Partners LLP cut its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 8.5% in the 1st quarter, Holdings Channel reports. The fund owned 1,138,371 shares of the medical research company’s stock after selling 106,010 shares during the period. Edwards Lifesciences accounts for about 1.3% of Liontrust Investment Partners LLP’s investment portfolio, making the stock its 28th biggest position. Liontrust Investment Partners LLP’s holdings in Edwards Lifesciences were worth $91,161,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences in the first quarter valued at about $25,000. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $25,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences during the 4th quarter worth approximately $26,000. RMG Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at approximately $26,000. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $27,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. UBS Group began coverage on shares of Edwards Lifesciences in a research note on Tuesday. They set a “buy” rating and a $110.00 price objective on the stock. JPMorgan Chase & Co. raised their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Finally, Piper Sandler reissued an “overweight” rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $83.98, for a total value of $85,575.62. Following the transaction, the vice president directly owned 33,682 shares in the company, valued at approximately $2,828,614.36. This trade represents a 2.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 44,558 shares of company stock valued at $3,770,939 over the last 90 days. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Trading Up 1.4%

NYSE:EW opened at $87.00 on Friday. The company has a market cap of $50.10 billion, a PE ratio of 50.00, a P/E/G ratio of 2.15 and a beta of 0.86. The business’s 50 day moving average is $87.91 and its two-hundred day moving average is $83.87. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.The business’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.